Anhedonia, self-experience in schizophrenia, and implications for treatment
- PMID: 14677076
- DOI: 10.1055/s-2003-45127
Anhedonia, self-experience in schizophrenia, and implications for treatment
Abstract
Anhedonia - the inability to experience pleasure - is a symptom of several psychiatric disorders such as depression, drug and alcohol dependence, but also schizophrenia. The concept of anhedonia played a major role in psychiatric and psychoanalytic explanations of psychotic behavior. The relationship between notions of anhedonia and of mental evolution and regression (in the work of Myerson and Bleuler) is discussed. The non-evolutionist views of Rado and Meehl are described. Then the concept of anhedonia is discussed in relationship to the phenomenological approach of Sass and Parnas, who view anhedonia as one manifestation of a self-disturbance or self-disorder that is fundamental in schizophrenia. Concerning treatment of anhedonia, it was often hypothesized that anhedonia is associated with a dysfunction of the mesolimbic dopaminergic reward system. However, studies in humans and non-human animal models indicate that dysfunction of central dopaminergic neurotransmission interferes with the process of motivation rather than with the ability to experience pleasure; the latter may be more mediated by the opioidergic and serotonergic neurotransmission. Understanding the neurobiological correlates of motivation and pleasure may provide new options to treat anhedonia in patients with schizophrenia.
Similar articles
-
Psychopathological correlates of reduced dopamine receptor sensitivity in depression, schizophrenia, and opiate and alcohol dependence.Pharmacopsychiatry. 2001 Mar;34(2):66-72. doi: 10.1055/s-2001-15184. Pharmacopsychiatry. 2001. PMID: 11302566 Clinical Trial.
-
[Anhedonia--a general nosology surmounting correlate of a dysfunctional dopaminergic reward system?].Nervenarzt. 1999 May;70(5):391-8. doi: 10.1007/s001150050454. Nervenarzt. 1999. PMID: 10407834 Review. German.
-
[Psychopathological correlates of dopaminergic dysfunction in alcoholic and schizophrenic patients].Nervenarzt. 1999 May;70(5):399-407. doi: 10.1007/s001150050455. Nervenarzt. 1999. PMID: 10407835 Review. German.
-
Anhedonia in schizophrenia: Deficits in both motivation and hedonic capacity.Schizophr Res. 2015 Oct;168(1-2):465-74. doi: 10.1016/j.schres.2015.06.019. Epub 2015 Jul 14. Schizophr Res. 2015. PMID: 26185892
-
Expected value and prediction error abnormalities in depression and schizophrenia.Brain. 2011 Jun;134(Pt 6):1751-64. doi: 10.1093/brain/awr059. Epub 2011 Apr 10. Brain. 2011. PMID: 21482548
Cited by
-
CACNA1C (Cav1.2) in the pathophysiology of psychiatric disease.Prog Neurobiol. 2012 Oct;99(1):1-14. doi: 10.1016/j.pneurobio.2012.06.001. Epub 2012 Jun 15. Prog Neurobiol. 2012. PMID: 22705413 Free PMC article. Review.
-
Late prenatal immune activation in mice leads to behavioral and neurochemical abnormalities relevant to the negative symptoms of schizophrenia.Neuropsychopharmacology. 2010 Nov;35(12):2462-78. doi: 10.1038/npp.2010.129. Epub 2010 Aug 25. Neuropsychopharmacology. 2010. PMID: 20736993 Free PMC article.
-
Developmental exposure of rats to chlorpyrifos leads to behavioral alterations in adulthood, involving serotonergic mechanisms and resembling animal models of depression.Environ Health Perspect. 2005 May;113(5):527-31. doi: 10.1289/ehp.7867. Environ Health Perspect. 2005. PMID: 15866758 Free PMC article.
-
Inhibition of the reward system by antipsychotic treatment.Dialogues Clin Neurosci. 2016 Mar;18(1):109-14. doi: 10.31887/DCNS.2016.18.1/gjuckel. Dialogues Clin Neurosci. 2016. PMID: 27069385 Free PMC article. Review.
-
The vulnerability to alcohol and substance abuse in individuals diagnosed with schizophrenia.Neurotox Res. 2006 Dec;10(3-4):235-52. doi: 10.1007/BF03033360. Neurotox Res. 2006. PMID: 17197373 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical